California voters will decide Proposition 38 on the November 3, 2026 ballot, which would authorize an $8.4 billion general obligation bond for immunology and immunotherapy research at public and nonprofit institutions, with half directed to cancer, heart disease, and Alzheimer’s. The measure qualified in June after signature collection led by philanthropist Gary Michelson and backed by disease advocacy groups. Trader sentiment favoring rejection reflects concerns over the $500–600 million annual General Fund repayment costs for roughly two decades, the initiative’s narrow drafting that channels significant funds to a single UCLA-affiliated institute meeting specific criteria, and broader resistance to voter-approved debt amid state budget pressures. Recent editorials have highlighted these structural features and the measure’s origin outside the legislative process as key factors weighing against passage.